title: Developmental study of miniature IPSCs of CA3 hippocampal cells: modulation by midazolam.
abstract: Maturation of GABAA/benzodiazepine receptors is associated with changes in their subunit composition. We have investigated whether these changes are accompanied by a developmental modification in the kinetic properties of miniature IPSCs (mIPSCs) and sensitivity to midazolam, a benzodiazepine agonist. In the presence of TTX (10 microM) and excitatory amino acid antagonists, AP5 (50 microM) and CNQX (50 microM), we whole-cell recorded mIPSCs in CA3 cells of hippocampal slices of adult and young (4-8 days) rats. mIPSCs were mediated by GABAA receptors as they were suppressed by bicuculline (10 microM). In both the adult and young rats, mIPSCs were similar in amplitude and kinetic properties. However, the mIPSCs frequency markedly increased with age from 4+/-3 Hz in the young rats to 20+/-9 Hz in the adult rats. In both age groups, midazolam (0.01 microM(-10) microM) and pentobarbital (30 microM) did not affect the amplitude, frequency and rise time of the mIPSCs but they increased to a similar extent their decay time constant. The current responses to isoguvacine, a GABAA agonist, were potentiated by 0.1 microM midazolam in both age groups. It is concluded that in immature and adult rats, synaptic GABAA receptors of CA3 were not different in their kinetic properties and sensitivity to midazolam.
authors: Institut des Neurosciences, Laboratoire de Neurobiologie du Developpement et du Vieillissement, UMR 7624, 9 quai St-Bernard, 75252, Paris Cedex 05, France. catherine.rovira@snv.jussieu.fr
authors: C
authors: C
authors: Rovira
authors: Y
authors: Y
authors: Ben-Ari
mesh_terms: D015763:2-Amino-5-phosphonovalerate / Q000494:pharmacology; D018750:6-Cyano-7-nitroquinoxaline-2,3-dione / Q000494:pharmacology; D000367:Age Factors; D000818:Animals; D001640:Bicuculline / Q000494:pharmacology; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D019706:Excitatory Postsynaptic Potentials / Q000502:physiology; D018755:GABA Agonists / Q000494:pharmacology; D018756:GABA Antagonists / Q000494:pharmacology; D018757:GABA Modulators / Q000494:pharmacology*; D006624:Hippocampus / Q000737:chemistry / Q000166:cytology* / Q000254:growth & development; D007539:Isonicotinic Acids / Q000494:pharmacology; D008297:Male; D008874:Midazolam / Q000494:pharmacology*; D009433:Neural Inhibition / Q000502:physiology*; D009474:Neurons / Q000737:chemistry* / Q000187:drug effects / Q000502:physiology; D009924:Organ Culture Techniques; D010424:Pentobarbital / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D011963:Receptors, GABA-A / Q000502:physiology*; D013779:Tetrodotoxin / Q000494:pharmacology
chemical_list: D018691:Excitatory Amino Acid Antagonists; D018755:GABA Agonists; D018756:GABA Antagonists; D018757:GABA Modulators; D007539:Isonicotinic Acids; D011963:Receptors, GABA-A; D013779:Tetrodotoxin; D018750:6-Cyano-7-nitroquinoxaline-2,3-dione; D015763:2-Amino-5-phosphonovalerate; D010424:Pentobarbital; D008874:Midazolam; D001640:Bicuculline; C015300:isoguvacine